

ZEUS - ziltivekimab Rx for atherosclerosis

Study location [BCDiabetes: 400 - 210 West Broadway, Vancouver V5Y 3W2](#)

Principal Investigator Dr. Tom Elliott; **Co-Principal Investigator** Dr. David Lee

Study coordinator & primary contact Alireza Moshiri P: 604-628-7253 x 7013:

amoshiri@bcdiabetes.ca

Summary: ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation

Hypothesis: Inflammation is an additional important risk factor to address in patients with established atherosclerotic cardiovascular disease (ASCVD), especially those with chronic kidney disease (CKD). Ziltivekimab once-monthly injection shots reduces inflammation as measured by high-sensitivity C-reactive protein (hs-CRP), and thereby has the potential to reduce cardiovascular risk.

Eligible Participants include:

- Male or female aged > 18
- eGFR 15-60
- Serum hsCRP \geq 2 mg/L
- Evidence of ASCVD within 5 yrs (documented MI, coronary or carotid revascularization, stroke, > 50% stenosis in a major epicardial coronary artery or carotid artery documented by catheterization, angiography or doppler ultrasound, PAD with ABI \leq 90 or > 50 % stenosis of a peripheral artery, lower extremity amputation due to atherosclerotic disease)

Treatment course and duration:

The study is designed as a randomized, parallel-group, double-blind, placebo-controlled, multi-center, multi-national CVOT designed to evaluate the effects of 15 mg ziltivekimab versus placebo (randomized 1:1), both administered s.c. once-monthly and added to standard of care, on CV outcomes in participants with established ASCVD, CKD and systemic inflammation.

Study goes for 3 years

Odds of receiving placebo 50%

Study documents:

[pre-screen informed consent](#)

[post-screen informed consent](#)

[Protocol](#)

Short URL = <https://bit.ly/3H6Xwcs>